Levitsky HI - Search Results

1

Tumors derived from antigen presenting cells.

Levitsky HI. Levitsky HI. Semin Immunol. 1996 Oct;8(5):281-7. doi: 10.1006/smim.1996.0036. Semin Immunol. 1996. PMID: 8956456 Free article. Review.

2

Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Huang AY, et al. Among authors: levitsky hi. J Exp Med. 1996 Mar 1;183(3):769-76. doi: 10.1084/jem.183.3.769. J Exp Med. 1996. PMID: 8642281 Free PMC article.

3

Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.

Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, Levitsky HI. Sotomayor EM, et al. Among authors: levitsky hi. Blood. 2001 Aug 15;98(4):1070-7. doi: 10.1182/blood.v98.4.1070. Blood. 2001. PMID: 11493453 Free article.

4

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Huang AY, et al. Science. 1994 May 13;264(5161):961-5. doi: 10.1126/science.7513904. Science. 1994. PMID: 7513904

5

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Lin KY, et al. Among authors: levitsky hi. Cancer Res. 1996 Jan 1;56(1):21-6. Cancer Res. 1996. PMID: 8548765

6

Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.

Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW. Levitsky HI, et al. J Immunol. 1996 May 15;156(10):3858-65. J Immunol. 1996. PMID: 8621924

7

Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses.

Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Huang AY, et al. Ciba Found Symp. 1994;187:229-40; discussion 240-4. doi: 10.1002/9780470514672.ch15. Ciba Found Symp. 1994. PMID: 7796673 Review.

8

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. Sotomayor EM, et al. Among authors: levitsky hi. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81. doi: 10.1073/pnas.96.20.11476. Proc Natl Acad Sci U S A. 1999. PMID: 10500201 Free PMC article.

9

Prostate cancer vaccines: current status.

Hwang LC, Fein S, Levitsky H, Nelson WG. Hwang LC, et al. Semin Oncol. 1999 Apr;26(2):192-201. Semin Oncol. 1999. PMID: 10597730 Review.

10

Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy.

Wu B, Wu JM, Miagkov A, Adams RN, Levitsky HI, Drachman DB. Wu B, et al. Among authors: levitsky hi. J Immunol. 2001 Apr 1;166(7):4773-9. doi: 10.4049/jimmunol.166.7.4773. J Immunol. 2001. PMID: 11254740

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

80 results

Search Page